Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus

被引:737
作者
Barrat, FJ [1 ]
Meeker, T
Gregorio, J
Chan, JH
Uematsu, S
Akira, S
Chang, B
Duramad, O
Coffman, RL
机构
[1] Dynavax Technol Corp, Berkeley, CA 94710 USA
[2] Osaka Univ, Res Inst Microbial Dis, Dept Host Def, Suita Ku, Suita, Osaka 5650871, Japan
关键词
D O I
10.1084/jem.20050914
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Raised serum levels of interferon (IFN)-alpha have been observed in systemic lupus erythematosus (SLE) patients, and these levels are correlated with both disease activity and severity. The origin of this IFN-alpha is still unclear, but increasing evidence suggests the critical involvement of activated plasmacytoid predendritic cells (PDCs). In SLE patients, DNA and RNA viruses, as well as immune complexes (ICs), that consist of autoantibodies specific to self-DNA and RNA protein particles can stimulate production of IFN-alpha. We have developed three series of oligonucleotide (ODN)-based inhibitors of Toll-like receptor (TLR) signaling. These ODNs include inhibitors of TLR9, inhibitors of TLR7 but not TLR9, and sequences that inhibit both TLR7 and TLR9. Specificity of these inhibitors is confirmed by inhibition of IFN-alpha production by PDCs in response to DNA or RNA viruses. We show that mammalian DNA and RNA, in the form of ICs, are potent self-antigens for TLR9 and TLR7, respectively, and induce IFN-alpha production by PDCs. This work suggests that TLRs may have a critical role in the promotion of lupus through the induction of IFN-alpha by PDCs. These inhibitors of TLR signaling thus represent novel therapeutic agents with potential for the treatment of lupus.
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 48 条
[1]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[2]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[3]   Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? [J].
Andreakos, E ;
Foxwell, B ;
Feldmann, M .
IMMUNOLOGICAL REVIEWS, 2004, 202 :250-265
[4]   Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus [J].
Baechler, EC ;
Batliwalla, FM ;
Karypis, G ;
Gaffney, PM ;
Ortmann, WA ;
Espe, KJ ;
Shark, KB ;
Grande, WJ ;
Hughes, KM ;
Kapur, V ;
Gregersen, PK ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2610-2615
[5]   Autoimmunity through cytokine-induced dendritic cell activation [J].
Banchereau, J ;
Pascual, V ;
Palucka, AK .
IMMUNITY, 2004, 20 (05) :539-550
[6]   FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG [J].
Båve, U ;
Magnusson, M ;
Eloranta, ML ;
Perers, A ;
Alm, GV ;
Rönnblom, L .
JOURNAL OF IMMUNOLOGY, 2003, 171 (06) :3296-3302
[7]   The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer [J].
Båve, U ;
Alm, GV ;
Rönnblom, L .
JOURNAL OF IMMUNOLOGY, 2000, 165 (06) :3519-3526
[8]   Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies [J].
Bengtsson, AA ;
Sturfelt, G ;
Truedsson, L ;
Blomberg, J ;
Alm, G ;
Vallin, H ;
Rönnblom, L .
LUPUS, 2000, 9 (09) :664-671
[9]   Interferon and granulopoiesis signatures in systemic lupus erythematosus blood [J].
Bennett, L ;
Palucka, AK ;
Arce, E ;
Cantrell, V ;
Borvak, J ;
Banchereau, J ;
Pascual, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) :711-723
[10]   Inferences, questions and possibilities in toll-like receptor signalling [J].
Beutler, B .
NATURE, 2004, 430 (6996) :257-263